Teachers Advisors’s Argos Therapeutics, Inc. ARGS Stock Holding History

Teachers Advisors’s Portfolio ARGS Stock Details ARGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-815	Closed	-$80K	–	3127
2016 Q4	$80K	Buy	815 +250	+44%	+$23.4K	﹤0.01%	3034
2016 Q3	$56K	Hold	565	–	–	﹤0.01%	3042
2016 Q2	$69K	Buy	+565	New	+$75.4K	﹤0.01%	3066
2014 Q2	–	Sell	-213	Closed	-$43K	–	3266
2014 Q1	$43K	Buy	+213	New	+$42.6K	﹤0.01%	3083

Other funds holding ARGS

Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

SMH

Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Teachers Advisors's ARGS Position: Q1 2017 in Review

Teachers Advisors sold out of Argos Therapeutics, Inc. (ARGS) in Q1 2017, closing a stake of 815 shares — an estimated $80K sold.

Teachers Advisors first reported a position in ARGS in Q1 2014 and held it in 4 quarters. The position peaked at $80K in Q4 2016. 43 funds tracked by Wall St. Rank hold ARGS as of Q1 2017.

Teachers Advisors reported no remaining Argos Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
Teachers Advisors sold 815 Argos Therapeutics, Inc. shares in Q1 2017, an estimated $80K.
Teachers Advisors first reported a position in Argos Therapeutics, Inc. in Q1 2014 and held it in 4 quarters.
Teachers Advisors's Argos Therapeutics, Inc. position peaked at $80K in Q4 2016.
43 funds tracked by Wall St. Rank held Argos Therapeutics, Inc. as of Q1 2017.

Based on Teachers Advisors's 13F filing for Q1 2017, filed 11 May 2017.